[A21-123] Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib and dexamethasone) - Addendum to Commission A21-60
Last updated 04.11.2021
Project no.:
A21-123
Commission:
Commission awarded on 30.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with multiple myeloma who have received at least one prior therapy
Result of dossier assessment:
Unchanged after addendum: Added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-60 | Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-11-04 A G-BA decision was published.
G-BA documents on this decision